Company intelligence / Profile preview

PeproTech

Cranbury/Rocky Hill, New Jersey, United Statespeprotech.com ↗

Ownership: Private
Employees: ~62
Development stage: Commercial

Overview

PeproTech manufactures high-quality recombinant proteins—primarily cytokines and growth factors—used globally in life science research and clinical development. Their GMP-grade products support the manufacture of advanced therapies including cell and gene therapies. The company does not have its own drug pipeline or clinical results as it supplies reagents rather than developing therapeutics.

Therapeutic areas: Other
Modalities: Recombinant proteinCytokineMonoclonal antibodyPolyclonal antibodyELISA kitCell culture media/supplement
Industry: Chemicals & Materials

Drug pipeline

1 asset

recombinant human Flt-3 ligand

Commercial

Indications: Research use, Cell therapy manufacturing

Partnerships

No specific major pharma partnerships disclosed; collaborates with academic/industry researchers to expand product lines

Beyond the preview

Go deeper on PeproTech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PeproTech.